The recombinant human cytokine interleukin-2 (rhIL-2, or aldesleukin) was originally approved as a drug for immune oncology targeting renal cell carcinoma (Klapper et al., 2008; Krieg et al., 2010). Here, IL2 is linked to hereditary clear cell renal cell carcinoma.